Seven to 18 months after Hemgenix, the mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by 54%.The most commonly reported side effects (incidence ≥5%) with this gene therapy were liver enzyme elevations, headache, elevated blood enzymes, flu-like symptoms, infusion-...